A Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS Mutation

16633TNG462-C102-NCT06922591OpenA Phase 1/2, Multicenter, Open-Label Study to Evaluate Safety, Tolerability & Antitumor Activity of TNG462 in Combination With Other Agents in Patients With Pancreatic or Non-Small Cell Lung Cancer With MTAP Loss & RAS MutationTNG462-C102NCT06922591IndustrialAdultTreatmentI/IIOtherNoel, MarcusGeorgetown University Medical Center : Princess Jones; Lombardi Comprehensive Cancer Center : Princess JonesGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC); Oncology PFS14509Princess JonesPrincess Jonespaj24@georgetown.edu2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>